2549. Dosing Antibiotics in the ICU
Session: Symposium: When Does PK/PD Matter for Patient Care?
Saturday, October 6, 2018: 2:00 PM
Room: S 305-314
Sujata M. Bhavnani, Pharm.D., M.S., ICPD, Schenectady, NY

Sujata M. Bhavnani, Pharm.D., M.S. is the Executive Vice President, Translational Medicine at the Institute for Clinical Pharmacodynamics, Schenectady, New York. Her work in anti-infective translational science involves the integration of pre-clinical pharmacokinetic-pharmacodynamic and early clinical pharmacokinetic data to identify dosage regimens that optimize the probability of positive clinical outcomes and minimize the potential of drug toxicities. Dr. Bhavnani’s extensive experience evaluating exposure-response relationships for antimicrobial agents using pre-clinical and clinical data has been used to support decisions for dose selection and interpretive criteria for in vitro susceptibility testing for numerous new drug applications. Dr. Bhavnani is the author or co-author of over 250 peer-reviewed scientific publications, book chapters, or scientific abstracts and an Associate Editor for Diagnostic Microbiology and Infectious Disease. Dr. Bhavnani serves as an advisor to the United States Antimicrobial Susceptibility Test Committee (USCAST). She has served on the IDWeek Program Planning Committee from 2012 to 2015, and is currently serving on the ASM-ESCMID Program Planning Committee (2017 to 2019).


Disclosures:

S. M. Bhavnani, Achaogen, Inc.: Research Contractor , Research support . Cellceutix Corporation: Research Contractor , Research support . Cempra Pharmaceuticals: Research Contractor , Research support . The Medicines Company: Research Contractor , Research support . Melinta Therapeutics: Research Contractor , Research support . Nabriva Therapeutics: Research Contractor , Research support . Paratek Pharmaceuticals: Research Contractor , Research support . Tetraphase Pharmaceuticals: Research Contractor , Research support . Zavante Therapeutics: Research Contractor , Research support .

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.